ResearcherLanzhou UniversityNo recent work listed

Wenlong Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6313-2241; OpenAlex author ID A5100453350. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. Co-author DOI 10.1155/2022/4661929 ↗
miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. Co-author DOI 10.3892/ijo.2015.3076 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wence Zhou · 1 shared paper, 2022 · strength 0.22
- Paper Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. DOI 10.1155/2022/4661929 ↗
Wenkai Jiang · 1 shared paper, 2022 · strength 0.22
- Paper Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. DOI 10.1155/2022/4661929 ↗
Yan Du · 1 shared paper, 2022 · strength 0.22
- Paper Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. DOI 10.1155/2022/4661929 ↗
Jianhua Zhang · 1 shared paper, 2015 · strength 0.06
- Paper miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. DOI 10.3892/ijo.2015.3076 ↗
Wei Lv · 1 shared paper, 2015 · strength 0.06
- Paper miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. DOI 10.3892/ijo.2015.3076 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.